OssDsign was founded in 2011 based on a collaboration between Uppsala University and Karolinska University and in 2019, the company was listed on Nasdaq First North Growth Market in Stockholm, Sweden.
For the first approximately 10 years, OssDsign was focused soley on its cranial patient-specific implant, OssDsign Cranial PSI. In November 2020, the company expanded into Orthobiologics through the acquisition of Sirakoss Ltd, who had developed a next generation nanosynthetic bone graft substitute designed to provide surgeons an easy-to-use and effective solution for treating skeletal defects with many applications including spinal fusion surgery.
Although indicated for broader use, the nanosynthetic bone graft, OssDsign Catalyst, was launched in the U.S. market late 2021 with a commercial focus on spinal surgery. In parallel, the company launched the first-in-patient clinical study TOP FUSION and with an ongoing commitment to clinical evidence, OssDsign subsequently in April 2022 launched its multi-center, prospective spinal fusion registry in the U.S., PROPEL, with the objective to evaluate the use and outcome of OssDsign Catalyst in real-world clinical practice.
In September 2023, in order to increase shareholder value, OssDsign announced a strategic shift to focus its operations solely on the Orthobiologics business. The new strategy resulted in OssDsign becoming a pure play Orthobiologics company in January 2024. This allows full focus on the nanosynthetic bone graft OssDsign Catalyst, an off-the-shelf product characterized by high scalability and high gross margins. All activities pertaining to the company’s patient-specific cranial implant business were consequently discontinued in a responsible manner at the end of December 2023.
